Mcvicar
Bruce Mcvicar, Pincourt CA
Patent application number | Description | Published |
---|---|---|
20090094128 | Multi-device supervisor support for self-checkout systems - A customer self-checkout system includes one or more checkout stations and multiple supervisor terminals. The supervisor terminals provide support to, and control over, the self- checkout system and checkout stations. A controller is used to coordinate communications among the checkout stations and supervisor terminals over a wired and/or wireless network interfaces. A user may provide input at supervisory terminal using an interface providing context sensitive prompting to enable control using a simple keyboard interface. | 04-09-2009 |
Daniel W. Mcvicar, Charles Town, WV US
Patent application number | Description | Published |
---|---|---|
20090137787 | JANUS FAMILY KINASES AND IDENTIFICATION OF IMMUNE MODULATORS - An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing. | 05-28-2009 |
20110177526 | JANUS FAMILY KINASES AND IDENTIFICATION OF IMMUNE MODULATORS - An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing. | 07-21-2011 |
Martin Mcvicar, County Monaghan IE
Patent application number | Description | Published |
---|---|---|
20100230201 | THREE-WHEEL FORKLIFT TRUCK - A forklift truck comprises two driven front wheels | 09-16-2010 |
20120323408 | STRADDLE CARRIER - A straddle carrier comprises a frame ( | 12-20-2012 |
Martin Mcvicar, Emyvale IE
Patent application number | Description | Published |
---|---|---|
20090145697 | FORKLIFT TRUCKS - A forklift truck ( | 06-11-2009 |
Megan E. Mcvicar, Portland, OR US
Patent application number | Description | Published |
---|---|---|
20140108370 | SEARCH QUERY EXPANSION AND GROUP SEARCH - Audio information is recorded in an overwriteable circular buffer of a computing device. Construction of a search query is initiated by receiving a user input. The user input includes one or more keywords forming a user-defined portion of the search query. At least a portion of the audio information recorded in the overwriteable circular buffer is processed to obtain one or more additional keywords forming an expanded portion of the search query. The portion of the audio information containing the additional keywords is received and recorded in the overwriteable circular buffer prior to receiving the user input. The search query including the user-defined portion and the expanded portion is supplied to a search engine. A response to the search query is received from the search engine. The response is generated by the search engine based on the user-defined portion and the expanded portion of the search query. | 04-17-2014 |
Nathaniel Sutton Mcvicar, St. Louis, MO US
Patent application number | Description | Published |
---|---|---|
20090182683 | Method and System for Low Latency Basket Calculation - A basket calculation engine is deployed to receive a stream of data and accelerate the computation of basket values based on that data. In a preferred embodiment, the basket calculation engine is used to process financial market data to compute the net asset values (NAVs) of financial instrument baskets. The basket calculation engine can be deployed on a coprocessor and can also be realized via a pipeline, the pipeline preferably comprising a basket association lookup module and a basket value updating module. The coprocessor is preferably a reconfigurable logic device such as a field programmable gate array (FPGA). | 07-16-2009 |
Scott Mcvicar, Sunnyvale, CA US
Patent application number | Description | Published |
---|---|---|
20100173372 | Recombinant Halohydrin Dehalogenase Polypeptides - The present disclosure provides engineered halohydrin dehalogenase (HHDH) polypeptides having improved enzyme properties as compared to the wild-type HHDH enzyme HheC and other reference engineered HHDH polypeptides. Also provided are polynucleotides encoding the engineered HHDH enzymes, host cells capable of expressing the engineered HHDH enzymes, and methods of using the engineered HHDH enzymes to synthesize a variety of chiral compounds including chiral epoxides and chiral alcohols. | 07-08-2010 |
20120220002 | Recombinant Halohydrin Dehalogenase Polypeptides - The present disclosure provides engineered halohydrin dehalogenase (HHDH) polypeptides having improved enzyme properties as compared to the wild-type HHDH enzyme HheC and other reference engineered HHDH polypeptides. Also provided are polynucleotides encoding the engineered HHDH enzymes, host cells capable of expressing the engineered HHDH enzymes, and methods of using the engineered HHDH enzymes to synthesize a variety of chiral compounds including chiral epoxides and chiral alcohols. | 08-30-2012 |
William K. Mcvicar, Sudbury, MA US
Patent application number | Description | Published |
---|---|---|
20090060917 | Carbamate Stereoisomer - The compound of formula (I) | 03-05-2009 |
20090060922 | Acetamide Stereoisomer - The compound of formula (I) | 03-05-2009 |
20100215589 | Carbamate Stereoisomer - The compound of formula (I) | 08-26-2010 |
20110172177 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE - The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A | 07-14-2011 |
20110245193 | COMBINATION COMPOSITIONS FOR REDUCING INTRAOCULAR PRESSURE - Provided herein is a pharmaceutical composition or a kit comprising a combination of a carbonic anhydrase inhibitor analog and an adenosine A | 10-06-2011 |
20110245195 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS - Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). | 10-06-2011 |
20110251151 | COMBINATION COMPOSITIONS FOR REDUCING INTRAOCULAR PRESSURE - Provided herein is a pharmaceutical composition or a kit comprising a combination of a non-selective beta-adrenergic receptor blocker and an adenosine A | 10-13-2011 |
20130196940 | ANHYDROUS POLYMORPHS OF [(2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAH- YDROFURAN-2-YL)} METHYL NITRATE AND PROCESSES OF PREPARATION THEREOF - The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate (Compound A). The present invention also provides processes for preparation of the anhydrous polymorphic forms of compound A. | 08-01-2013 |
20130296607 | Acetamide Stereoisomer - The compound of formula (I) | 11-07-2013 |
20140018314 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS - Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). | 01-16-2014 |
20140135300 | Acetamide Stereoisomer - The compound of formula (I) | 05-15-2014 |
20140271876 | OPHTHALMIC FORMULATIONS - The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof. | 09-18-2014 |
20140275128 | METHOD OF PROVIDING OCULAR NEUROPROTECTION - Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for preventing, reducing or treating retinal ganglion cell damage comprising administering an effective amount of a purine derivative to a subject in need thereof. | 09-18-2014 |
20150038448 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE - The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A | 02-05-2015 |
20150080330 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS - Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). | 03-19-2015 |